IJBPAS, August, 2025, 14(8): 4333-4343

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

A COMPREHENSIVE REVIEW OF THE AI ADVANCEMENTS IN INTEGRATION FOR THE MEDICINAL PRODUCT LIFE CYCLE

PATEL V, CHAKRABORTHY GS* AND PATEL P

Parul Institute of Pharmacy and Research, Faculty of Pharmacy, Parul University, Vadodara, Gujarat, 391760.

***Corresponding Author: Dr. G.S Chakraborthy: E Mail:** g.chakraborthy19159@paruluniversity.ac.in

Received 20th April 2024; Revised 14th May 2024; Accepted 1st Sept. 2024; Available online 1st Aug. 2025

https://doi.org/10.31032/IJBPAS/2025/14.8.9292

ABSTRACT

Artificial intelligence (AI) is rapidly transforming the landscape of drug development. The traditional medicinal product life cycle, from target identification to post-marketing surveillance, is undergoing a transformation driven by Artificial Intelligence (AI). This review explores the current advancements in integrating AI across various stages of drug development. We analyse how AI is revolutionizing target discovery, accelerating drug design, optimizing clinical trials, and enhancing post-marketing safety monitoring. The review highlights the potential benefits of AI, including increased efficiency, improved accuracy, and personalized medicine approaches. We also acknowledge the challenges associated with AI integration, such as data quality concerns, regulatory considerations, and the need for human-AI collaboration. Finally, the review discusses future directions for AI in the pharmaceutical industry, emphasizing the potential for a more data-driven and efficient drug development process. This review provides a comprehensive picture of the current state-of-the-art and the exciting possibilities that AI holds for the future of drug development, life-saving medicines to market.

Keywords: Artificial Intelligence, Lifecycle of Medicinal Product, Product life cycle management, Future Prospects

INTRODUCTION:

The development of new medicines is a notoriously slow and expensive process. Traditionally, bringing a single drug to market can take over a decade and cost billions of dollars. However, recent advancements in Artificial Intelligence (AI) offer a glimmer of hope for revolutionizing the medicinal product life cycle. AI,

encompassing machine learning and deep learning techniques, is rapidly transforming various stages of drug discovery and development **[1]**. This review article provides a comprehensive analysis of how AI is being integrated across the medicinal product life cycle, exploring its impact on each stage.

We will delve into how AI is accelerating target identification, optimizing drug design, streamlining clinical trials, and enhancing post-marketing surveillance. We will discuss the specific applications of AI at each stage, highlighting the benefits and potential challenges associated with this integration. This review aims to provide a clear picture of the current landscape of AI in drug development, its transformative potential, and the considerations for its successful implementation.

HISTORY AND CLASSIFICATION OF ARTIFICIAL INTELLIGENCE : [9]

Early Enthusiasm and the First AI Winter (1956-1980s):

Following its formalization in 1956, AI research experienced a period of rapid growth and optimism. However, by the early 1970s, limitations in computing power and the complexity of replicating human-like intelligence became apparent. A 1973 report by James Light hill, critical of overly ambitious goals, further dampened enthusiasm. Consequently, AI research funding declined, leading to the field's first "winter" in the 1970s **[2, 3]**.

Shifting Focus: Expert Systems and the Second AI Winter (1970s-1990s):

The 1970s saw a shift towards more practical applications with the emergence of expert systems. These systems aimed to mimic human expertise in specific domains by encoding knowledge and reasoning capabilities. While initially successful, expert systems ultimately faced limitations such as a lack of general knowledge, difficulty in knowledge acquisition, and overly simplistic reasoning methods. These limitations led to a second decline in AI research funding in the late 1980s **[4, 5]**.

The Rise of Big Data and Deep Learning: A New Era for AI (1990s-Present):

The rise of the internet in the 1990s renewed interest in AI's potential. However, it wasn't until the late 2000s, with the explosion of data volume fuelled by mobile internet and cloud computing, that AI truly revolutionized various fields. The development of deep learning algorithms, a type of artificial neural network, marked a significant turning point. Deep learning's ability to learn from vast amounts of data enabled AI to beat human performance in many tasks, ushering in a new era of AI advancement **[6, 7]**.



Figure 1: History of Artificial Intelligence [8]

CLASSIFICATION OF ARTIFICAL INTELLIGENCE:



Figure 2: Classification of Artificial Intelligence [8]



Figure 3: Classification of Perception [8]



Figure 4: Classification of Congnition and Learning [8]

AI IN THE LIFECYCLE OF MEDICINAL PRODUCTS:

Drug Discovery:-

Imagine sifting through mountains of data – genomics, protein structures and disease models – to identify promising drug candidates. AI tackles this challenge with ease, performing massive data analysis to pinpoint potential breakthroughs. Additionally, AI simulations can predict how drugs interact with the body, reducing reliance on animal testing and speeding up the process **[11, 12]**.

Pre-clinical Trials:-

AI takes centre stage again with virtual screening. Here, AI simulates drug interactions with target molecules, saving time and resources compared to traditional methods. Furthermore, AI can predict potential toxicity risks before animal testing even begins, refining the selection process for the most promising candidates **[13, 14]**.

Clinical Trials:-

Matching the right patients to the right trials is paramount. AI steps in by analysing genetic and medical history data to identify ideal candidates. This leads to more efficient trials with targeted patient groups. AI can also optimize trial design, ensuring they gather the most relevant data in the shortest time possible. Real-time data monitoring during trials is another area where AI shines, allowing researchers to identify potential safety issues quickly **[15, 16]**.

Product Information:-

Clear and accurate product information is vital for safe and effective medication use. AI assists in drafting, compiling, and translating this information, ensuring regulatory compliance while saving valuable time. However, human review remains crucial for accuracy and transparency.

Manufacturing:-

Predictive maintenance powered by AI can prevent equipment failures and optimize production processes **[17]**. Additionally AI-powered quality control automates visual inspections, ensuring consistency and catching defects with eagle eyes **[18]**.

Post-Authorization Phase:-

The journey doesn't end after a drug hits the market. AI continues to play a vital role in pharmacovigilance by analysing reports of adverse events. This allows for quicker identification of safety signals, ensuring patient well-being. Real-world data analysis using AI can also provide valuable insights into how patients actually use the medication, leading to improvements in drug effectiveness **[19, 20]**.

AI METHODS IN PRODUCT LIFECYCLE MANAGEMENT [18]:

Table 1: AI methods in Product Lifecycle Management

Stage	AI Method	Description	Benefit
Planning and Ideation	Natural Language Processing (NLP)	Analysis vast amounts of unstructured data like customer reviews, social media conversations, and market research reports to identify product needs and emerging trends.	Uncovers hidden insights for innovation and helps prioritize features customers truly value.
	Machine Learning (ML)	Leverages historical data and market trends to predict market demand and identify potential product failures before development begins.	Reduces development risks by allocating resources efficiently and focusing on ideas with higher chances of success.
Design and Development	Generative Design	Utilizes AI algorithms to automatically generate multiple design options based on specified criteria like functionality, materials, and manufacturing constraints.	Accelerates the design iteration process by exploring a broader range of possibilities in a shorter timeframe.
	Computer-Aided Engineering (CAE) with Machine Learning	Integrates machine learning algorithms into CAE simulations to optimize product performance for factors like strength, weight, and heat dissipation.	Improves product quality by identifying potential weaknesses early in the design phase and reducing development time.
Manufacturing and Production	Predictive Maintenance	Analyses data from sensors on equipment to predict failures before they occur, allowing for proactive maintenance scheduling.	Minimizes downtime and production disruptions, optimizing overall production efficiency.
	Industrial Robotics with AI	Integrates AI into industrial robots, enabling them to learn and adapt to changing conditions on the assembly line.	Increases production flexibility by allowing robots to handle variations in product components and improve product quality through consistent and precise movements.
Service and Support	Chat bots and Virtual Assistants	Utilizes chat bots powered by AI to provide 24/7 customer support, answer product-related questions, and troubleshoot issues.	Improves customer satisfaction by offering readily available assistance and reduces service costs by automating routine tasks.
	Sentiment Analysis	Analysis customer feedback from various sources like surveys and social media to understand their opinions and identify areas for product improvement and service enhancement.	Enables continuous product improvement by gathering valuable customer insights and fostering a culture of customer-centricity.

DEVELOPING TRENDS OF PRODUCT LIFE CYCLE MANAGEMENT:

1. Data-driven Decision Making:

- **Smart data collection and sharing:** AI facilitates collecting and analysing vast amounts of data across the entire product lifecycle. This data can come from sensors in products, manufacturing processes, customer interactions, and more **[21]**. By sharing this data effectively across different stages of PLM, companies can make more informed decisions about design, production, operation, and maintenance.
- **Predictive analytics**: AI algorithms can analyse historical data and real-time information to predict future events,

such as equipment failure, customer churn, or changes in market demand **[22]**. This allows for proactive maintenance, targeted marketing campaigns, and adjustments to product design or features.

- **AI-powered design tools**: AI can assist in product design by analysing user data, competitor products, and market trends to suggest optimal features and functionalities.

2. Digital Twin Technology:

- **Virtual product simulations:** Digital twins, virtual replicas of physical products, can be used to simulate real-world scenarios and performance **[23]**. This allows for testing and optimizing product designs before physical prototypes are built, saving time and resources.
- **Predictive maintenance:** By monitoring a product's digital twin and real-time sensor data, AI can predict potential malfunctions and schedule maintenance before they occur. This minimizes downtime and maintenance costs.
- **Improved product lifecycle management:** Digital twins provide a centralized platform for managing all product data throughout its lifecycle **[24]**. This allows for better collaboration between different teams and easier access to information needed for informed decision-making.

3. Other Emerging Trends:

- **AI-powered supply chain management:** AI can optimize logistics and inventory management by analysing data on supplier performance, transportation routes, and demand forecasts **[25]**. This leads to a more efficient and cost-effective supply chain.
- **Closed-loop product lifecycle:** AI can help companies design products that are easier to disassemble, recycle, and reuse. This contributes to a more sustainable product lifecycle by reducing waste and environmental impact.
- **Personalized customer experiences:** AI can analyse customer data to personalize product recommendations, provide targeted support, and anticipate customer needs **[26]**. This fosters stronger customer relationships and loyalty.

FUTURE PROSPECTS:

The potential of data-driven decision-making and digital twin technology to revolutionize product lifecycle management (PLM). By **utilizing** smart enabling technologies, information sharing across all PLM stages can be significantly enhanced, leading to more informed and precise lifecycle management choices.

Data-driven intelligence throughout PLM:

This includes investigating data and knowledge-based approaches for product design, production, operation, maintenance, supply chain management, and intelligent production decision support systems **[27]**. Research should also explore new concepts, models, and methods for sustainable PLM, incorporating AI-powered manufacturing and operation decision-making alongside innovative design, manufacturing, service, and maintenance strategies.

Digital twin-driven smart products for PLM:

Digital twins, virtual representations of physical assets, offer significant promise for smart manufacturing. Future research should investigate the application of digital twins in all stages of PLM, including design, production, operation, maintenance, and data management **[28]**. This exploration can extend to human-machine collaboration, sustainable smart manufacturing, and innovative modelling and simulation technologies for digital twins.

ADVANTAGES AND CHALLENGES: [29, 30]

Advantages:

Increased Efficiency and Productivity: AI automates tasks, optimizes processes, and minimizes errors, leading to significant gains in efficiency and productivity.

Improved Quality and Reduced Costs: AI-powered quality control and predictive maintenance ensure higher product quality and minimize downtime and waste, leading to cost savings.

Enhanced Customer Experience: Proactive maintenance, personalized service recommendations, and faster issue resolution through AI lead to a more positive customer experience.

Data-Driven Decision: AI provides valuable insights from data, enabling data-driven decisions for product development, service planning, and resource allocation

Challenges and Considerations:

- Data quality, transparency, and explainability of AI models are crucial aspects to address.
- Ethical considerations surrounding potential bias in data and algorithms require careful attention.
- Robust data security measures are paramount to protect sensitive patient information.

CONCLUSION:

AI is revolutionizing drug development by streamlining processes, enhancing efficacy, and accelerating the journey of medications from discovery to patient access.

The review analyses specific AI applications future for each stage, from drug discovery and preclinical development to clinical

trials, regulatory processes, and post-marketing surveillance.

- Potential benefits of AI in drug development include:
- Increased efficiency and faster drug development timelines
- Improved drug efficacy and patient safety
- More targeted clinical trials
- Enhanced data-driven decision making

The integration of AI throughout the medicinal product life cycle presents a transformative era for drug discovery and development. From pinpointing novel drug targets to optimizing clinical trials and streamlining manufacturing, AI offers a powerful toolkit to accelerate innovation and improve patient outcomes. While challenges regarding data quality, interpretability, and regulatory hurdles remain, ongoing advancements are paving the way for a future where AI becomes an indispensable partner in bringing safe and effective therapies to patients faster and more efficiently. As AI continues to evolve and its integration deepens, the medicinal product life cycle stands to be fundamentally reshaped, ushering in a new paradigm of personalized medicine and improved global health.

REFERENCES:

[1] Farghali H, Canová NK, Arora M. The potential applications of artificial intelligence in drug discovery and development. Physiological Research. 2021 Dec;70(Suppl 4):S715.

[2] Lighthill J. Artificial intelligence: a paper symposium. Science Research Council, London. 1973.

[3] McCarthy J, Minsky ML, Rochester N, Shannon CE. A proposal for the dartmouth summer research project on artificial intelligence, august 31, 1955. AI magazine. 2006 Dec 15;27(4):12-.

[4] Feigenbaum EA. The simulation of reasoning. Computers and Thought. 1963;29–70.

[5] Lenat DB. Can machines really think? Scientific American. 1984;251:84–92.

[6] Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to prevent neural networks from overfitting. The journal of machine learning research. 2014 Jan 1;15(1):1929-58.

[7] Brynjolfsson E, McAfee A. The second machine age: Work, progress, and prosperity in a time of brilliant technologies. WW Norton & Company; 2014 Jan 20.

[8] Wang L, Liu Z, Liu A, Tao F. Artificial intelligence in product lifecycle management. The International Journal of Advanced

Manufacturing Technology. 2021 May;114:771-96.

[9] Haenlein M, Kaplan A. A brief history of artificial intelligence: On the past, present, and future of artificial intelligence. California management review. 2019 Aug;61(4):5-14.

[10] Gobble MM. The road to artificial general intelligence. Research-Technology Management. 2019 May 4;62(3):55-9.

[11] Ekins JP. In silico drug discovery: techniques and applications. Nature reviews Drug discovery. 2003;2:880–8.

[12] Machine learning for drug discovery: challenges and solutions. Chembiochem: European Journal of Chemical Biology. 2016;17:1799–811.

[13] Liu J. A critical review of computational methods for virtual screening. Current medicinal chemistry. 2006;13(3):343–86.

[14] Macher OA. Navigating the pitfalls of applying machine learning to preclinical safety assessment. Nature reviews Drug discovery. 2020;19:309–24.

[15] Gilad Y, Shalit U. Applying machine learning to clinical trial design. Nature reviews Drug discovery. 2021;20:305–20

[16] Liu X. Real-world applications of artificial intelligence in clinical trials: a systematic review. Journal of medical Internet research. 2021;23(7).

[17] Qi Q. A literature review of intelligent manufacturing and cyber-physical systems. Journal of Manufacturing Science and Engineering. 2017;139.

[18] Bandyopadhyay S, Chandra S. Applications of artificial intelligence in modern manufacturing. International Journal of Performability Engineering. 2020;16:1537–50.

[19] Shah NH. Incorporating real-world data into regulatory decision-making. Nat Rev Drug Discov. 2020;19(2):128–38.

[20] Lindley SJ. Building a new architecture for global pharmacovigilance using artificial intelligence. Drug safety. 2020;43:937–45.

[21] Lee J, Bagheri B, Kao H-A. of Cyber-Physical Systems (CPS) which is a foundation for data-driven decision. Manufacturing Letters. 2015;3(1):18–23.

[22] Singh J. A review of industrial additive manufacturing (AM) in context of sustainability. The International Journal of Advanced

Manufacturing Technology. 2018;95(9–12):4051–69.

[23] Tao F. Digital twins and cyber-physical systems towards service manufacturing. Journal of Manufacturing Science and Engineering. 2019;141(1).

[24] Negri S. Digital twin: Manufacturing guide for digital transformation. Elsevier; 2017.

[25] Kamath R, Prakash R. Artificial intelligence in supply chain management: A review. International Journal of Production Research. 2018;56(18):5732–40.

[26] Jawahir IS. Circular economy in the construction industry: A review. Journal of Cleaner Production. 2020;272.

[27] Xu L. Product lifecycle management for smart manufacturing. Journal of Manufacturing Systems. 2019;54:708–24.

[28] Tao F. Digital twins driven product design, manufacturing and service for smart products. CIRP Journal of Manufacturing Science and Technology. 2020;10(4):233–44.

[29] Lee J, Bagheri B, Kao H-A. A cyber-physical systems architecture for industry 4.0 manufacturing systems. Manufacturing Letters. 2015;3(1):18–23.

[30] Jobin A. The murky waters of algorithmic bias in healthcare. Nature Biotechnology. 2019;37(4):340–4.